This activity has expired. Credit is no longer available.
This activity was supported by educational grants from AbbVie Inc. and Pfizer Inc.
Current and Future Directions in PARP Inhibition
Megan E. Grudem, APRN, CNP
Mayo Clinic
Andrea E. Wahner Hendrickson, MD
Mayo Clinic
Review how far PARP inhibition has come and discover where it’s headed, including its potential role in various malignancies, how to select patients who are appropriate candidates, and guidance on devising treatment plans that include PARP inhibitors for patients with ovarian or breast cancer based on genetic profiles, tolerability, dosing schedules, and other factors.
|
|
These activities, certified for CME/CE/CPE credit, are jointly provided by
  |
in collaboration with
  |